<DOC>
	<DOC>NCT01413204</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.</brief_summary>
	<brief_title>Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This is a randomized, 3-arm, parallel group, double blind study to evaluate the efficacy and safety of TA-7284 in Japanese patients with Type 2 diabetes mellitus, who are not optimally controlled on diet and exercise. The patients will receive either TA-7284-Low, TA-7284-High or Placebo orally alone for 24 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Men or women age ≥20 years old Diagnosed with Type 2 diabetes mellitus at least 3 months before runin period HbA1c of ≥7.0% and ≤10.0% Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus Past or current history of severe diabetic complications Fasting plasma glucose &gt; 270 mg/dL before treatment start History of hereditary glucosegalactose malabsorption or primary renal glucosuria Patients requiring insulin therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TA-7284</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Sodium Glucose Co-transporter (SGLT2 inhibitor)</keyword>
</DOC>